证券研究报告|医药生物 投资要点： ⚫ 全球和中国的 CXO 市场稳定增长。据弗若斯特沙利文预测，2026 年全球和中国临床前 CRO 市场规模将分别达到 332.5 亿美元和 528.6 亿人民币，2026 年全球和中国临床 CRO 市场规模将分别达 到 732.0 亿美元和 598 亿人民币，市场逐渐恢复与稳定增长。全 球医药 CDMO 行业的市场规模预计在 2026 年和 2033 年将分别达 到 1189 亿美元和 3385 亿美元。中国 CDMO 市场规模增速远高于全 球增速，中国医药 CDMO 行业的市场规模预计在 2026 年和 2033 年 将分别达到 1370 亿人民币和 5369 亿人民币。 ⚫ 行业集中度加速提升，头部企业凭借全产业链与全球化布局构筑 坚实护城河。2025 年，药明康德预计营收达 454.56 亿元（同比 增长 15.84%），药明康德净利率自 2020 年的 18.06%稳步攀升至 2025Q1-Q3 的 37.15%，显著高于行业整体水平（21.67%–22.99%）。 中小企业出清退场，行业已形成以药明康德、泰格医药、康龙化 成、凯莱英为第一梯队，昭衍新药、九洲药业 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 董事會會議召開日期 無錫藥明康德新藥開發股份有限公司（「本公司」，連同其子公司「本集團」）董 事會（「董事會」）謹此宣佈將於2026年3月23日（星期一）召開董事會會議，以考 慮及批准（其中包括）本集團截至2025年12月31日止年度全年業績，及建議之末 期股息（如有），以及處理任何其他事項。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2026年3月9日 於本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博 士、詹智玲女士及冷雪松先生。 * 僅供識別 ...

（股份代號：2359） 董事會會議召開日期 無錫藥明康德新藥開發股份有限公司（「本公司」，連同其子公司「本集團」）董 事會（「董事會」）謹此宣佈將於2026年3月23日（星期一）召開董事會會議，以考 慮及批准（其中包括）本集團截至2025年12月31日止年度全年業績，及建議之末 期股息（如有），以及處理任何其他事項。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 香港，2026年3月9日 於本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博 士、詹智玲女士及冷雪松先生。 * 僅供識別 ...

Summary of Key Points from the Conference Call Records Industry Overview - The conference call focuses on the **pharmaceutical and medical device industry** for Q1 2026, highlighting performance disparities among companies like **Angelalign** and **Eli Lilly**, with profits exceeding 40% due to successful global operations and innovation [1][2]. Core Insights and Arguments - **Performance Disparities**: The pharmaceutical sector shows significant performance differences, with companies like **Angelalign** and **Eli Lilly** achieving over 40% profit growth, validating the logic of global operations and profit realization [1]. - **Investment Strategy**: The strategy for March 2026 shifts towards companies with strong annual report performance expectations, reducing the valuation weight of early pipeline projects, and increasing allocations to **CXO** and medical consumption sectors [1][2]. - **Haikang's Key Data Catalysts**: Haikang is expected to release critical Phase II data for CFB (IgA nephropathy) and THbeta (MASH) in H1 2026, which could lead to significant market expectations [1][4]. - **Federal Pharmaceutical's UBT251 Pipeline**: The strategic position of UBT251 is enhanced as Novo Nordisk accelerates its overseas Phase II trials, potentially narrowing the gap with similar products [1][2]. - **CXO Sector Premium**: The leading position of **WuXi AppTec** is highlighted, with a historical high discount of 10% between A/H shares, indicating strengthened competitive positioning in the medium term [1][2]. - **Medical Device Exports**: **Precision Medical** has over 60% of its orders from overseas, with expectations to increase its market share from 5% to 20% [1][2]. Additional Important Insights - **Eli Lilly's Financial Performance**: Eli Lilly reported Q1 2026 revenue of 1.5 billion, a 41.2% year-on-year increase, with net profit expected to reach approximately 600 million, reflecting a 44% growth [2][12]. - **Haikang's Pipeline Details**: Haikang's pipeline includes five major products with significant Phase II data expected in 2026, including PDE34 for COPD and oral TH beta for liver penetration [4][5]. - **Market Trends**: The overall market sentiment reflects a disconnect between stock prices and industry progress, with a focus on companies entering profit realization phases [2][3]. - **Regulatory Environment**: Changes in regulatory requirements for liver penetration may facilitate faster progression for Haikang's TH beta project [6][7]. - **Federal Pharmaceutical's Recovery Signals**: The company is expected to see recovery in its core business, with raw material prices stabilizing and animal health business growth anticipated in 2026 [7][8]. - **Medical Device Market Dynamics**: **Precision Medical** is positioned as a leader in surgical robotics, with significant growth in overseas orders and market share potential [14][15]. Conclusion The conference call provides a comprehensive overview of the pharmaceutical and medical device sectors, emphasizing the importance of innovation, global operations, and strategic positioning in navigating market challenges and opportunities. Key companies are highlighted for their strong performance and potential for future growth, particularly in the context of upcoming data releases and regulatory changes.

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 510,476,909 | RMB | | 1 RMB | | 510,476,909 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 510,476,909 | RMB | | 1 RMB | | 510,476,909 | | 2. 股份分類 | 普通股 | 股份類別 | A | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 本月底法定/註冊股本總額： RMB 2,983,757,155 備註： 第 1 頁 共 11 頁 v 1.2.0 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 510,476,909 | RMB | | 1 RMB | | 510,476,909 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 510,476,909 | RMB ...

Core Insights - The top three companies with the highest short positions as of February 20 are China COSCO Shipping (01919) at 18.86%, CATL (03750) at 16.68%, and Ping An Insurance (02318) at 15.48% [1][2] Group 1: Top Short Positions - China COSCO Shipping (01919) has a short position of 520 million shares, representing a short ratio of 18.86% [2] - CATL (03750) has a short position of 26.0064 million shares, with a short ratio of 16.68% [2] - Ping An Insurance (02318) has a short position of 1.153 billion shares, with a short ratio of 15.48% [2] - Sunny Optical Technology (02382) has a short ratio of 15.24% [2] - Dongfang Electric (01072) has a short ratio of 15.12% [2] - ZTE Corporation (00763) has a short ratio of 14.53% [2] - Vanke (02202) has a short ratio of 14.16% [2] - Zijin Mining (02899) has a short ratio of 13.50% [2] - Hansoh Pharmaceutical (01276) has a short ratio of 13.32% [2] - WuXi AppTec (02359) has a short ratio of 12.50% [2] Group 2: Largest Increases in Short Positions - Weimob (02013) saw an increase of 0.27% in its short ratio, now at 12.43% [2] - China Duty Free Group (01880) increased by 0.25%, now at 8.92% [2] - Midea Group (00300) increased by 0.23%, now at 4.26% [2] - Meitu (01357) increased by 0.22%, now at 8.21% [2] - Xinjiang Xinxin Mining (03833) increased by 0.20%, now at 0.51% [2] - Hua Hong Semiconductor (01347) increased by 0.20%, now at 3.59% [2] - Minmetals Development (00425) increased by 0.19%, now at 2.59% [2] - China COSCO Energy (01138) increased by 0.18%, now at 6.61% [2] - Jiaxin International Resources (03858) increased by 0.17%, now at 0.25% [2] - China Railway (00390) increased by 0.17%, now at 4.61% [2] Group 3: Largest Decreases in Short Positions - Pacific Basin Shipping (02343) decreased by 0.83%, now at 4.66% [3] - Tianqi Lithium (09696) decreased by 0.66%, now at 2.25% [3] - Tiangong International (00826) decreased by 0.51%, now at 3.46% [3] - Huiju Technology (01729) decreased by 0.50%, now at 3.08% [3] - Shengye (06069) decreased by 0.44%, now at 1.63% [3] - Ganfeng Lithium (01772) decreased by 0.29%, now at 8.52% [3] - China Galaxy (06881) decreased by 0.25%, now at 3.19% [4] - Jiangxi Copper (00358) decreased by 0.22%, now at 2.32% [4] - China COSCO Shipping (01919) decreased by 0.21%, now at 18.86% [4] - Cafe de Coral (00341) decreased by 0.19%, now at 5.43% [4]

Group 1 - The Hang Seng Index rose by 0.95%, while the Hang Seng Tech Index increased by 0.56% [1] - New World Development saw a rise of over 7%, WuXi Biologics increased by over 5%, SenseTime rose nearly 5%, and China Shenhua Energy gained over 4% [1] - Longfor Group, CSPC Pharmaceutical Group, and WuXi AppTec all experienced gains of over 3% [1]

| 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( *) 买入营业部 | | | | 卖出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-02-27 | 药明康德 | 603259 | 98.01 254.83 | 2.6 | 机构专用 | 發開手落在過程貨 | | Ka | 2月27日，药明康德大宗交易成交2.6万股，成交额254.83万元，占当日总成交额的0.11%，成交价98.01 元，较市场收盘价98.01元持平。 ...

Group 1 - The core viewpoint of the article highlights the recent strong performance of several biopharmaceutical stocks, particularly in the Hong Kong market, with innovative drug concepts becoming increasingly active [1] - WuXi AppTec (药明合联) led the sector with a rise of over 8%, while WuXi Biologics (药明生物) increased by over 5%, and other companies like CanSino Biologics (康方生物), Genscript Biotech (云顶新耀), and Innovent Biologics (诺诚健华) saw gains exceeding 4% [1] - According to Guolian Minsheng Securities, the innovative drug business development (BD) transactions in China are expected to continue the high growth trend seen in 2025, indicating a robust upward momentum in the industry [1] Group 2 - The stock performance data shows that WuXi AppTec (02268) increased by 8.40% to a latest price of 63.250, with a total market capitalization of 795.68 billion [2] - WuXi Biologics (02269) rose by 5.38% to 40.340, with a market cap of 1,669.08 billion, reflecting a year-to-date increase of 28.31% [2] - Other notable performers include CanSino Biologics (09926) up by 4.81%, Genscript Biotech (01952) up by 4.27%, and Innovent Biologics (69660) up by 4.04%, indicating a positive trend across the sector [2]